AstraZenecaAstraZeneca plans to conduct further development of AZD3480 by initiating Phase IIb studies in attention deficit/hyperactivity disorder (ADHD) and has agreed to make a $10 million milestone payment to Targacept. AstraZeneca also plans to continue development of AZD1446 (TC-6683) for Alzheimer's disease. AZD1446 is currently in Phase 1 and was discovered in the ongoing AstraZeneca-Targacept research collaboration.

For Alzheimer's disease, development of AZD1446 has been prioritized by AstraZeneca over further development of AZD3480. AZD3480 and AZD1446 are selective alpha4beta2 NNR agonists.

About selective alpha4beta2 NNR agonists
AZD3480 and AZD1446 are designed to selectively activate a specific subtype (alpha4beta2) of neuronal nicotinic receptor (NNR). These NNRs are found on nerve cells throughout the central nervous system (CNS). They control the flow of positively charged ions into the neurons, and thus serve as key regulators of neuronal signaling and CNS activity. Alpha4beta2 NNRs have been associated with a number of neurological conditions.

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: